Integrated longevity intelligence

Your biology is not one number.
It is several layers — read together.

Aevum brings your permanent genome, a curated longevity signature, your current pace of ageing and your clinical biomarkers into a single interpreted report — and keeps reinterpreting it as science and your biology change.

30×
Whole-genome sequencing depth — sequenced once
183
Curated longevity-associated variants, evidence-graded
4
Biological layers read against one another
Reinterpreted as evidence accumulates
The problem

Today you can buy fragments of the picture

Every category on the market answers part of the question. None of them answers it together, unless you can afford a clinic programme.

01

Blood platforms

Current biomarkers and a blood-derived “biological age”.

No genome. No methylation clock. Nothing inherited.

02

Epigenetic age tests

A single methylation clock reading.

One signal, with nothing to read it against.

03

Consumer genome kits

Sequencing, sometimes at depth.

Disease-risk output relabelled as longevity; no current biology.

04

Premium clinics

Depth, imaging and physician time.

Typically $10,000–25,000 and tied to physical visits.

The result is a customer holding one isolated signal, a shallow DNA readout, a generic age score — or an invoice for a clinic programme. Aevum occupies the space in between.

What we combine

Four layers, one interpretation

What is permanent, what is changing, and what deserves attention — held in the same frame.

01

The permanent genome

30× whole-genome sequencing

Sequenced once at clinical depth. Germline predisposition, carrier status and pharmacogenomics — the layer that never has to be repeated.

Permanent
02

Inherited longevity biology

Curated 183-variant signature

Variants associated with exceptional survival and lifespan, each carrying an effect size and a confidence tier rather than a headline claim.

Permanent
03

How fast you appear to be ageing

True DNA-methylation age

An epigenetic clock from the same blood draw as your biomarkers. Repeatable, which is what makes the direction of travel readable.

Changes
04

Your current biology

Clinical blood biomarkers + history

Guideline-referenced laboratory values and your health history — later, wearable data — showing what your predispositions are doing right now.

Changes
Proprietary signature

183 longevity variants, honestly graded

Not a disease-risk report renamed “longevity”, and not the two or three famous genes every kit ships.

Each variant in the signature is selected for association with exceptional longevity, survival or parental lifespan — then assessed on evidence strength, effect size, replication across cohorts and relevance to your population.

Effects in longevity genetics are small. We report them that way. Variants sit in confidence tiers; uncertain markers are not forced into a score, and correlated variants are not counted twice.

The purpose is not to predict a date. It is an evidence-graded view of inherited longevity biology.

How the signature is built
Signature composition · illustrative
Current — stronger evidence61
Emerging research74
Watch — monitored, unscored33
Archive — retired on new evidence15
183
curated variants
148
genes / loci
4
confidence tiers
The report

See how a finding is actually presented

One finding at a time: what was measured, how strong the evidence is, what it means, what it does not mean, and what is worth watching.

AEVUM
Example data — not a real person
Biological layers
Genome
Longevity signature
Pace of ageing
Blood biomarkers
Stronger evidenceGenome

Inherited tendency toward higher circulating LDL cholesterol

A polygenic pattern across well-replicated lipid loci places this illustrative profile in the upper part of the distribution for genetically influenced LDL-C.

Genetically influenced LDL-C tendency
Lower tendencyHigher tendency

Percentile within the reference population used for this illustration

What this means

Lipid levels are likely to sit higher than average for a given lifestyle, so lipid values are worth watching earlier and more regularly than usual.

What this does not mean

It is not a diagnosis of hyperlipidaemia or cardiovascular disease, and it does not fix a future outcome. Predisposition describes tendency, not destiny.

Signals agree across layers

Blood layer agrees: measured ApoB sits above the optimal range, so the inherited tendency appears to be expressed today.

Worth monitoring or discussing

Lipid panel including ApoB and Lp(a), reviewed against current guideline thresholds with a clinician.

Every statement in the report links to the evidence and the interpretation version behind it.
Walk through the full report All values shown are illustrative
Integration, not data dumping

Hundreds of values become a short, ordered picture

The work is not producing more numbers. It is deciding which few matter, and why.

Where signals agree

An inherited tendency that is visibly expressed in current biomarkers carries far more weight than either signal alone.

Where signals disagree

A favourable genome alongside an unfavourable current measurement is not a contradiction to hide — it points to what is changeable.

Where nothing is happening

Most findings need no action. Saying so clearly is part of the value; a report that flags everything flags nothing.

The category map

Where each approach reaches — and stops

A factual comparison of what categories of product typically include.

Capability
Blood platforms
Biomarker panels
Epigenetic age tests
Single clock
Consumer WGS kits
Sequencing-led
Premium longevity clinics
In-person programmes
Aevum
Integrated report
30× whole genome
Longevity-specific genetics
True methylation age
Clinical blood biomarkers
Interpretation across layers
Longitudinal reinterpretation
Accessible outside a clinic programme

Included · Partial · Not included. Describes typical scope of each category of product, not the specifications of any individual company, which vary and change.

It improves with time

Sequenced once. Re-read for years.

Your genome does not change. Almost everything used to interpret it does.

New replicated studies, a repeated methylation measurement, a fresh biomarker panel, later your wearable data — each addition sharpens the reading of data you already gave once. Aevum is a record that matures, not a PDF that ages.

Illustrative timeline
  1. 01
    Baseline

    30× genome, longevity signature, methylation age, blood panel — the first integrated read.

  2. 02
    Month 12

    Repeat blood and methylation. Direction of change becomes the signal.

  3. 03
    Year 2

    Signature re-scored against newly replicated evidence. Retired markers removed.

  4. 04
    Ongoing

    Each new layer re-reads the genome you already sequenced.

Standards behind the reading

AI can organise and explain evidence. It does not create it.

Every interpretation is linked to published evidence, graded for confidence, version-controlled and explicit about its limits.

Evidence-linked

Each statement traces to the studies behind it.

Confidence-graded

Strength of evidence is shown, never implied.

Version-controlled

You can see which interpretation produced a finding.

Limits stated

What the data cannot tell you is written down.

Validation and interpretation standards
Waiting list

Be among the first to see your complete picture

The waiting list opens access in small first groups, onboarded personally, whose reports shape how Aevum presents evidence. No purchase today — tell us where you are starting from.